Hidradenitis Suppurativa: New Targets and Emerging Treatments

Hidradenitis Suppurativa: New Targets and Emerging Treatments

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can be challenging to treat. Biologics and targeted small molecules have become an increasingly popular area of investigation for therapeutic development for moderate-to-severe HS, though only three biologics—adalimumab, sec...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical dermatology Vol. 25; no. 5; pp. 765 - 778
Main Authors: Gao, Julia L., Otto, Tracey S., Porter, Martina L., Kimball, Alexa B.
Format: Journal Article
Language:English
Published: Cham Springer International Publishing 01-09-2024
Springer Nature B.V
Subjects:
Abscesses
Antibiotics
Biological products
Clinical trials
Cytokines
Dermatology
Drug dosages
FDA approval
Infections
Medicine
Medicine & Public Health
Pharmacology/Toxicology
Pharmacotherapy
Psoriasis
Review Article
Surgery
Tumor necrosis factor-TNF
United States > US
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can be challenging to treat. Biologics and targeted small molecules have become an increasingly popular area of investigation for therapeutic development for moderate-to-severe HS, though only three biologics—adalimumab, secukinumab, and bimekizumab—have received US Food and Drug Administration (FDA) or European Medicines Evaluation Agency approval for treating HS. Promising agents under investigation are targeting interleukin 17A/F, JAK/STAT pathway, interleukin 36, interleukin 1, and more.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1175-0561
1179-1888
1179-1888
DOI:10.1007/s40257-024-00880-1